Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/14200
Title: | Balancing benefits and risks in the era of biologics | Authors: | Adami G. Saag K. Chapurlat R. Guañabens N. Haugeberg G. Lems W. Matijević, Radmila Peel N. Poddubnyy D. Geusens P. |
Issue Date: | 1-Jan-2019 | Journal: | Therapeutic Advances in Musculoskeletal Disease | Abstract: | © The Author(s), 2019. Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab. | URI: | https://open.uns.ac.rs/handle/123456789/14200 | ISSN: | 1759720X | DOI: | 10.1177/1759720X19883973 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
7
checked on Nov 20, 2023
Page view(s)
28
Last Week
7
7
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.